Impact of breast cancer subtypes and treatment on survival: an analysis spanning two decades
- PMID: 22989461
- PMCID: PMC3467337
- DOI: 10.1158/1055-9965.EPI-12-0474
Impact of breast cancer subtypes and treatment on survival: an analysis spanning two decades
Abstract
Background: We investigated the impact of breast cancer molecular subtypes and treatment on survival in a cohort of medically insured women followed for more than 20 years.
Methods: We examined 934 female members of an integrated health care delivery system newly diagnosed with invasive breast cancer between 1988 and 1995 and followed them through 2008. Tumors were classified into four molecular subtypes on the basis of their expression profile: luminal A; luminal B; basal-like; and HER2-enriched. We followed women from the surgery date to death, health plan disenrollment, or study's end. HR and 95% confidence intervals (CI) were fit using Cox proportional hazards models adjusting for cancer treatments and tumor characteristics.
Results: A total of 223 (23.9%) women died because of breast cancer during the 21-year study period. Compared with women with luminal A tumors, women with HER2-enriched (HR 2.56, 95% CI 1.53-4.29) and luminal B tumors (HR 1.96, 95% CI: 1.08-3.54) had roughly a two-fold increased adjusted risk of breast cancer mortality. In addition, the survival curves suggest that risk of late mortality persists in women with luminal A tumors.
Conclusion: Among women with health care coverage, molecular subtypes were important predictors of breast cancer mortality. Women with HER2-enriched tumors and luminal B subtypes had the poorest survival despite adjusting for important covariates.
Impact: In a cohort followed for more than 20 years, women with HER2-enriched tumors had worse survival, but interestingly, the survival curve for women with luminal A tumors continued to steadily decline after 10 years of follow-up.
2012 AACR
Figures
Similar articles
-
Impact of molecular subtype and race on HR+, HER2- breast cancer survival.Breast Cancer Res Treat. 2021 Oct;189(3):845-852. doi: 10.1007/s10549-021-06342-0. Epub 2021 Jul 31. Breast Cancer Res Treat. 2021. PMID: 34331630 Free PMC article.
-
PAM50- and immunohistochemistry-based subtypes of breast cancer and their relationship with breast cancer mortality in a population-based study.Breast Cancer. 2021 Nov;28(6):1235-1242. doi: 10.1007/s12282-021-01261-w. Epub 2021 May 18. Breast Cancer. 2021. PMID: 34003448
-
Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study.Breast Cancer Res Treat. 2011 Feb;126(1):185-92. doi: 10.1007/s10549-010-1113-7. Epub 2010 Aug 14. Breast Cancer Res Treat. 2011. PMID: 20711652 Free PMC article.
-
Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort.Int J Cancer. 2019 Mar 15;144(6):1251-1261. doi: 10.1002/ijc.31950. Epub 2018 Dec 3. Int J Cancer. 2019. PMID: 30367449
-
Survival time and molecular subtypes of breast cancer after radiotherapy in Thailand.Asian Pac J Cancer Prev. 2014;15(23):10505-8. doi: 10.7314/apjcp.2014.15.23.10505. Asian Pac J Cancer Prev. 2014. PMID: 25556500
Cited by
-
Immunohistochemistry-derived subtypes of breast cancer distribution in four regions of Ethiopia.Front Endocrinol (Lausanne). 2023 Nov 9;14:1250189. doi: 10.3389/fendo.2023.1250189. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 38027092 Free PMC article.
-
Proteome profiling of triple negative breast cancer cells overexpressing NOD1 and NOD2 receptors unveils molecular signatures of malignant cell proliferation.BMC Genomics. 2019 Feb 21;20(1):152. doi: 10.1186/s12864-019-5523-6. BMC Genomics. 2019. PMID: 30791886 Free PMC article.
-
The prognostic impact of age in different molecular subtypes of breast cancer: a population-based study.PeerJ. 2019 Jul 4;7:e7252. doi: 10.7717/peerj.7252. eCollection 2019. PeerJ. 2019. PMID: 31309004 Free PMC article.
-
CDK4/6 inhibitors for primary endocrine resistant HR-positive/HER2-negative metastatic breast cancer: a case report.Transl Breast Cancer Res. 2023 Oct 7;4:33. doi: 10.21037/tbcr-23-27. eCollection 2023. Transl Breast Cancer Res. 2023. PMID: 38751470 Free PMC article.
-
Modeling luminal breast cancer heterogeneity: combination therapy to suppress a hormone receptor-negative, cytokeratin 5-positive subpopulation in luminal disease.Breast Cancer Res. 2014 Aug 13;16(4):418. doi: 10.1186/s13058-014-0418-6. Breast Cancer Res. 2014. PMID: 25116921 Free PMC article.
References
-
- American Cancer Society. Cancer Facts & Figures 2012. Atlanta: American Cancer Society; 2012.
-
- Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295:2492–502. - PubMed
-
- Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–52. - PubMed
-
- Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J, et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med. 2010;7:e1000279. - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous